255 related articles for article (PubMed ID: 23096411)
1. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
2. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
3. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis.
Li J; Shen J; Wang Z; Xu H; Wang Q; Chai S; Fu P; Huang T; Anas O; Zhao H; Li J; Xiong N
Sci Rep; 2019 Sep; 9(1):13904. PubMed ID: 31554859
[TBL] [Abstract][Full Text] [Related]
4. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
[TBL] [Abstract][Full Text] [Related]
5. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
6. Experimental validation of 5 in-silico predicted glioma biomarkers.
Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
[TBL] [Abstract][Full Text] [Related]
7. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
8. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
9. The Fibronectin Expression Determines the Distinct Progressions of Malignant Gliomas via Transforming Growth Factor-Beta Pathway.
Chen CW; Yang CH; Lin YH; Hou YC; Cheng TJ; Chang ST; Huang YH; Chung ST; Chio CC; Shan YS; Cheng HC; Chang WT
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917452
[TBL] [Abstract][Full Text] [Related]
10. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of Hypoxia-Related Genes in Primary Brain Tumors and Correlation with Clinicopathologic Data.
Bayat S; Mamivand A; Khoshnevisan A; Maghrouni A; Shabani S; Raouf MT; Yaseri M; Saffar H; Tabrizi M
World Neurosurg; 2021 Oct; 154():e465-e472. PubMed ID: 34303851
[TBL] [Abstract][Full Text] [Related]
12. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
14. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme.
Dai S; Wang X; Li X; Cao Y
Biochem Biophys Res Commun; 2015 Nov; 467(2):204-10. PubMed ID: 26449464
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
Han Z; Jia J; Lv Y; Wang R; Cao K
Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
[TBL] [Abstract][Full Text] [Related]
17. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
18. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.
Serban F; Daianu O; Tataranu LG; Artene SA; Emami G; Georgescu AM; Alexandru O; Purcaru SO; Tache DE; Danciulescu MM; Sfredel V; Dricu A
J Immunoassay Immunochem; 2017; 38(1):21-33. PubMed ID: 27379831
[TBL] [Abstract][Full Text] [Related]
19. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
20. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]